Amphastar Pharmaceuticals AMPH Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Amphastar Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's net debt / EBITDA?
- Amphastar Pharmaceuticals (AMPH) reported net debt / EBITDA of 3× in Q1 2026.
- How has Amphastar Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Amphastar Pharmaceuticals's net debt / EBITDA increased by 56.4% year-over-year, from 1.9× to 3×.
- What is the long-term trend for Amphastar Pharmaceuticals's net debt / EBITDA?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's net debt / EBITDA has grown at a 26.4% compound annual growth rate (CAGR), from -0.8× to 2.5×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.